Robert Dickey

Robert Dickey is currently Director at GSNO Therapeutics, Inc. He is Chief Financial Officer & Director at SFA Therapeutics, Inc. since 2021.
He is Chief Financial Officer at AIM ImmunoTech, Inc. since 2022.
He is Chief Financial Officer at Exxel Pharma, Inc. starting in 2025.
Former roles include Chief Executive Officer & Chief Operating Officer at Protarga, Inc., Managing Director at Lehman Brothers, Inc., Director at EMI Holding, Inc. from 2018 to 2019, Director at Sanuthera, Inc. from 2013 to 2017, Managing Director at Legg Mason Wood Walker, Inc., Managing Director at Danforth Advisors LLC from 2018 to 2020, Independent Director at Emmaus Life Sciences, Inc. from 2019 to 2022, Independent Director at AngioGenex, Inc., Principal at Neuromedical Systems, Inc., Senior Vice President at AIM ImmunoTech, Inc. from 2008 to 2013, Chief Financial Officer & Senior Vice President at StemCyte, Inc., Chief Financial Officer at Invitae Corp.
in 2023, Chief Financial Officer & Vice President-Finance at Tyme Technologies, Inc. from 2015 to 2017, Chief Financial Officer at Locus Pharmaceuticals, Inc., Chief Financial Officer at Caladrius Biosciences, Inc. from 2013 to 2015, Chief Financial Officer at Motif Bio Plc from 2017 to 2018, Chief Financial Officer at Tyme, Inc. from 2015 to 2017, Chief Financial Officer at BeyondSpring Pharmaceuticals, Inc., Chief Financial Officer at NLS Pharmaceutics Ltd. from 2019 to 2021, Chief Financial Officer at Enveric Biosciences, Inc. from 2022 to 2023, and Chief Financial Officer at Vyome Holdings, Inc. from 2025 to 2026.
Education includes undergraduate degree from Princeton University and MBAistration from The Wharton School of the University of Pennsylvania.